EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients

Yufeng Song iD, Regan Myers, Frances Mehl iD, Lila Murphy, Bailey Brooks, Jeffrey M Wilson, Alexandra Kadl, Judith Woodfolk, Steven L Zeichner iD

mBio · 2024

DOI: 10.1128/mbio.00541-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Yufeng Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Manning Fund For COVID-19 Research, Ivy Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Many mechanisms responsible for COVID-19 pathogenesis are well-established, but COVID-19 includes features with unclear pathogenesis, such as autonomic dysregulation, coagulopathies, and high levels of inflammation. The receptor for the SARS-CoV-2 spike protein receptor-binding domain (RBD) is angiotensin-converting enzyme 2 (ACE2). We hypothesized that some COVID-19 patients may develop antibodies that have a negative molecular image of RBD sufficiently similar to ACE2 to yield ACE2-like catalytic activity—ACE2-like abzymes. To explore this hypothesis, we studied patients hospitalized with COVID-19 who had plasma samples available obtained about 7 days after admission. ACE2 is a metalloprotease that requires Zn 2+ for activity. However, we found that the plasma from some patients studied could specifically cleave a synthetic ACE2 peptide substrate, even though the plasma samples were collected using disodium EDTA anticoagulant. When we spiked plasma with synthetic ACE2, no ACE2 substrate cleavage activity was observed unless Zn 2+ was added or the plasma was diluted to decrease EDTA concentration. After processing samples by 100 kDa size exclusion columns and protein A/G adsorption, which depleted immunoglobulin by >99.99%, the plasma samples did not cleave the ACE2 substrate peptide. The data suggest that some patients with COVID-19 develop antibodies with abzyme-like activity capable of cleaving synthetic ACE2 substrate. Since abzymes can exhibit promiscuous substrate specificities compared to the enzyme whose active site image they resemble, and since proteolytic cascades regulate many physiologic processes, anti-RBD abzymes may contribute to some otherwise obscure COVID-19 pathogenesis. IMPORTANCE We provide what we believe to be the first description of angiotensin-converting enzyme 2 (ACE2)-like enzymatic activity associated with immunoglobulin in COVID-19 patients. COVID-19 includes many puzzling clinical features that have unclear pathogenesis, including a hyperinflammatory state, abnormalities of the clotting cascade, and blood pressure instability. We hypothesized that some patients with COVID-19 patients may produce antibodies against SARS-CoV-2 with enzymatic activity, or abzymes, that target important proteolytic regulatory cascades. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein binds ACE2 on the surface of the future host cell. This means that the RBD has a negative molecular image of ACE2. We hypothesized that some antibodies produced against the RBD would have, in turn, a negative molecular image of the RBD sufficiently similar to ACE2 to have ACE2-like catalytic activity. In other words, some anti-RBD antibodies would be ACE2-like abzymes. Abzymes elicited by SARS-CoV-2 infection have the potential to affect host physiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme 2COVID-19HumansAntibodiesPeptidesProtein BindingSARS-CoV-2Spike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

ACE2COVID-19SARS-CoV-2abzyme

Substanzen

Angiotensin-Converting Enzyme 2AntibodiesPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2 protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, University of Virginia, Charlottesville, Virginia, USA.
  • College of Arts and Sciences, University of Virginia, Charlottesville, Virginia, USA.
  • Division of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Yufeng Song, Frances Mehl, Steven L Zeichner

Förderung

  • NIAID NIH HHS
  • Manning Fund For COVID-19 Research
  • Ivy Foundation
  • Pendleton Laboratory for Pediatric Infectious Disease
  • University of Virginia College Council Minerva Research Grant
  • HHS | National Institutes of Health
  • HHV-6 Foundation

Zitieren

APA

Song, Y., Myers, R., Mehl, F., Murphy, L., Brooks, B., Wilson, J. M., Kadl, A., Woodfolk, J., & Zeichner, S. L. (2024). ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients. mBio. https://doi.org/10.1128/mbio.00541-24

Vancouver

Song Y, Myers R, Mehl F, Murphy L, Brooks B, Wilson JM, et al. ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients. mBio. 2024. doi:10.1128/mbio.00541-24

BibTeX
@article{Song2024,
  author = {Song, Yufeng and Myers, Regan and Mehl, Frances and Murphy, Lila and Brooks, Bailey and Wilson, Jeffrey M and Kadl, Alexandra and Woodfolk, Judith and Zeichner, Steven L},
  title = {ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.00541-24}
}
Kostenlos starten →